^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR1 (Fibroblast growth factor receptor 1)

    i
    Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
    6d
    Case Report: FGFR1 mutation and massive chromosome loss drive malignant transformation of low-grade gliomas. (PubMed, Front Oncol)
    Similar haploidy is found in 3 additional high-grade astrocytoma by literature review, all harbor a single gene mutation in the MAPK pathway. We propose that the massive chromosome loss might serve as a significant mechanism contributing to the unusual malignant transformation of benign brain tumors activated by the MAPK pathway.
    Journal
    |
    BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1) • NF1 (Neurofibromin 1)
    |
    BRAF mutation • FGFR mutation
    9d
    Synthesis, biological evaluation, and molecular docking of novel coumarin-based bisimine derivatives. (PubMed, Sci Rep)
    Spectroscopic characterization (NMR, IR, MS) confirmed their unique architectures, with 3j emerging as a standout candidate exhibiting anticancer activity comparable to doxorubicin but with superior selectivity against MCF-7 and A549 cell lines...Molecular docking revealed robust interactions between lead compounds (3b, 3c, 3j) and key therapeutic targets (FGFR1, cIAP1-BIR3), suggesting a dual inhibitory mechanism. These findings underscore the potential of coumarin bisimines as versatile platforms for addressing antibiotic resistance and oxidative stress-related pathologies.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    doxorubicin hydrochloride
    9d
    5'tRF-GlyGCC Promotes Breast Cancer Progression via LDHA-Mediated Glycolysis and Macrophage Polarization. (PubMed, Adv Sci (Weinh))
    In vivo, targeting 5'tRF-GlyGCC/LDHA signaling significantly suppresses tumor growth and enhances the efficacy of immunotherapy. Collectively, these findings elucidate the pivotal role of 5'tRF-GlyGCC in BC progression, highlighting its potential as therapeutic target for BC treatment.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • LDHA (Lactate dehydrogenase A)
    10d
    Genomic and Demographic Characteristics of Angiosarcoma as Described in the AACR Project GENIE Registry. (PubMed, Cancers (Basel))
    In one of the largest genomic analyses of angiosarcoma to date, we identified recurrent alterations, suggesting potential future therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH2 (Notch 2) • FAT1 (FAT atypical cadherin 1) • FLT4 (Fms-related tyrosine kinase 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • POT1 (Protection of telomeres 1) • MSI2 (Musashi RNA Binding Protein 2) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TP53 mutation • PIK3CA mutation • CDKN2A deletion
    12d
    Non-small cell lung carcinoma with co-expression of thyroid transcription factor-1 and p40: a case report and literature review. (PubMed, World J Surg Oncol)
    NSCLC with co-expression of Thyroid Transcription Factor-1 and p40 is a rare and diagnostically challenging subtype, most frequently observed in older male patients with a history of smoking and predominantly arising in peripheral lung regions. The morphological, immunophenotypic and molecular features of these tumors suggest that they may originate from stem-like basal cells with dual-lineage differentiation. Literature review identified high-frequency alterations in TP53, FGFR1, CDKN2A, EGFR, KRAS, MYC, NF1 and AKT1. Next-generation sequencing-based genomic profiling facilitate the diagnosis and treatment of such cases.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • LRP1B (LDL Receptor Related Protein 1B) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NKX2-1 (NK2 Homeobox 1) • SOX2 • TP63 (Tumor protein 63)
    |
    TP53 mutation
    14d
    ALKBH5 demethylation modification of SE-lncRNA ZMIZ1-AS1 promotes FGFR1-mediated proliferation and invasive metastasis in osteosarcoma. (PubMed, Cell Mol Life Sci)
    Notably, combined inhibition of ALKBH5 (using ALKBH5-IN-5) and FGFR1 (using BGJ398/infigratinib) synergistically suppressed ZMIZ1-AS1-driven oncogenesis in vivo. Our study establishes the ALKBH5/ZMIZ1-AS1/PTBP1/FGFR1 signaling axis as a key driver of osteosarcoma progression and a promising target for therapeutic intervention.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • PTBP1 (Polypyrimidine Tract Binding Protein 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase)
    |
    Truseltiq (infigratinib)
    16d
    A novel splicing variant of CNTRL::FGFR1 in myeloid/lymphoid neoplasm with eosinophilia and rearrangement of FGFR1. (PubMed, J Hematop)
    This novel splicing variant involves an in-frame fusion between exon 38 of CNTRL and exon 11 of FGFR1, retaining the kinase domain of FGFR1 and leading to its constitutive activation. Despite multiple treatment regimens, the patient failed to achieve complete remission (CR). Conclusion The findings highlight the urgent need for targeted therapies, such as FGFR inhibitors, to improve outcomes in patients with FGFR1-rearranged malignancies.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    17d
    Integrated bioinformatics analysis to elucidate cellular communication in the microenvironment of breast cancer. (PubMed, Discov Oncol)
    In the tumor microenvironment of breast cancer, intercellular communication pairs of different cell types and molecules can exacerbate the development of breast cancer. among them, through the present study, we found that CXCL12-CXCR4 and FGF7-FGFR1 are the most important. Also, most significantly differentially expressed genes including CHRDL1, SCARA5, LYVE1, PI16, and SAA2 seemed to play a critical role in these mechanisms and immune cell infiltration, shaping the TME of BC.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • SAA2 (Serum Amyloid A2) • PI16 (Peptidase Inhibitor 16) • FGF7 (Fibroblast Growth Factor 7) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
    18d
    Single-cell transcriptomic profiling reveals liver fibrosis in colorectal cancer liver metastasis. (PubMed, Exp Mol Med)
    Here we present a comprehensive single-cell atlas of tumor fibrosis in LM, revealing the intricate multicellular environment and molecular features associated with it. These insights deepen our understanding of tumor fibrosis mechanisms and inform improved clinical diagnosis and treatment strategies.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGF23 (Fibroblast Growth Factor 23)
    18d
    Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes. (PubMed, Leukemia)
    We sequenced genomic DNA from patients (n = 20) with a known or suspected TK gene fusion and identified rearrangements in 18 cases, including all cases with a known TK fusion, typical and atypical BCR::ABL1 rearrangements, an 843Kb deletion causing a FIP1L1::PDGFRA fusion, novel AGAP2::PDGFRB and NFIA::PDGFRB fusions, and a complex CCDC88C::PDGFRB rearrangement with multiple translocation events. The approach was fast (<72 h/sample from DNA to result), flexible with minimal hands-on laboratory time, and provided accurate, patient-specific characterisation of genomic breakpoints.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • CCDC88C (Coiled-Coil Domain Containing 88C)
    |
    FIP1L1-PDGFRA fusion
    19d
    Multiclass machine learning models for molecular subtype identification of pediatric low-grade glioma using bi-institutional MRIs for precision medicine. (PubMed, NPJ Precis Oncol)
    The best-performing model achieved an average one-vs-the-rest area under receiver operating characteristic curve of 0.819 (95% confidence interval &lsqb;0.791, 0.848]). This study highlights the potential of radiomics-based ML models for molecular subtype differentiation in pLGG, with per-patient predictions enabling outlier identification and subgroup performance evaluation.
    Journal
    |
    BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    24d
    The Role of FGFR3 in the Progression of Bladder Cancer. (PubMed, Cancers (Basel))
    Functionally, the FGFR inhibitor erdafitinib suppressed cell proliferation and migration, and FGFR3 silencing also markedly reduced proliferation, migration, invasion, and colony formation in cancer cell lines. The down-regulation of FGFR3 in muscle-invasive bladder cancer, coupled with the inhibitory effect of its inactivation on cell growth, suggests a significant role for FGFR3 in bladder cancer progression.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    Balversa (erdafitinib)